Humoral immunity in DiGeorge syndrome - PubMed (original) (raw)
Humoral immunity in DiGeorge syndrome
A K Junker et al. J Pediatr. 1995 Aug.
Abstract
Objective: To assess humoral immunity after immunization and natural infection in patients with clinical manifestations of the DiGeorge anomalad.
Design: Retrospective review of cases.
Setting: Ambulatory immunology clinic of a tertiary care teaching hospital.
Patients: The 13 patients had a symptom complex including congenital heart disease, characteristic facies of the DiGeorge anomalad, possible hypocalcemia, and thymic hypoplasia or aplasia. Molecular and cytogenic studies of 12 patients demonstrated that all had 22q11 microdeletions.
Methods: Serial studies included lymphocyte population enumeration by flow cytometry, lymphocyte proliferation assays with the mitogens phytohemagglutinin and pokeweed mitogen and Staphylococcus aureus, and immunoglobulin quantitation. Specific antibody studies included virus neutralization assays for poliovirus antibodies, and enzyme-linked immunosorbent assay for diphtheria, tetanus, measles, rubella, varicella-zoster virus (VZV), and cytomegalovirus (CMV) antibodies. Avidity of rubella, VZV, and CMV antibodies was tested by enzyme-linked immunosorbent assay modified to include a mild protein denaturant in the first wash after incubation with sera.
Results: All patients had a CD3+ cell count greater than 0.500 x 10(9)/L and a CD4+ cell count greater than 0.350 x 10(9)/L). One patient had low proliferation responses to S. aureus, and one to phytohemagglutinin and pokeweed mitogen. Immunoglobulin levels, compared with those in age-related control subjects, were normal except that two patients had transient, borderline low IgG levels and two had elevated IgA levels. Specific antibody tests showed (No. of patients with positive results/No. tested) the following: diphtheria (13/13); tetanus (13/13); poliomyelitis caused by polio virus type 1 (5/9), type 2 (9/9), and type 3 (8/9); measles (11/13); rubella (11/13); and infection with VZV (5/5) and CMV (7/13). There were no significant differences in antibody avidity results between patients and control subjects for rubella (mean avidity index, 83.5 +/- 8.79 vs 85 +/- 17.6), VZV (81.6 +/- 3.98 vs 65.1 +/- 12.38), or CMV (69.3 +/- 22.31 vs 73.3 +/- 12.46).
Conclusions: Patients with "partial" DiGeorge anomalad, defined by clinical and immunologic criteria, can be immunized and for the most part can generate good antibody responses.
Similar articles
- Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE. Perez EE, et al. Pediatrics. 2003 Oct;112(4):e325. doi: 10.1542/peds.112.4.e325. Pediatrics. 2003. PMID: 14523220 - [Live Vaccine in Children with DiGeorge/22q11.2 Deletion Syndrome].
Miranda M, Martins AT, Carvalho S, Serra-Caetano A, Esteves I, Marques JG. Miranda M, et al. Acta Med Port. 2019 Aug 1;32(7-8):514-519. doi: 10.20344/amp.9802. Epub 2019 Aug 1. Acta Med Port. 2019. PMID: 31445531 Portuguese. - Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome.
Davis CM, Kancherla VS, Reddy A, Chan W, Yeh HW, Noroski LM, Rosenblatt H, Shearer WT, Chinen J. Davis CM, et al. J Allergy Clin Immunol. 2008 Dec;122(6):1194-9. doi: 10.1016/j.jaci.2008.06.039. Epub 2008 Sep 13. J Allergy Clin Immunol. 2008. PMID: 18789819 - DiGeorge syndrome/chromosome 22q11.2 deletion syndrome.
Sullivan KE. Sullivan KE. Curr Allergy Asthma Rep. 2001 Sep;1(5):438-44. doi: 10.1007/s11882-001-0029-z. Curr Allergy Asthma Rep. 2001. PMID: 11892070 Review. - DiGeorge syndrome/velocardiofacial syndrome: the chromosome 22q11.2 deletion syndrome.
Sullivan KE. Sullivan KE. Adv Exp Med Biol. 2007;601:37-49. doi: 10.1007/978-0-387-72005-0_4. Adv Exp Med Biol. 2007. PMID: 17712990 Review.
Cited by
- Clinical Practice Guidelines for the Immunological Management of Chromosome 22q11.2 Deletion Syndrome and Other Defects in Thymic Development.
Mustillo PJ, Sullivan KE, Chinn IK, Notarangelo LD, Haddad E, Davies EG, de la Morena MT, Hartog N, Yu JE, Hernandez-Trujillo VP, Ip W, Franco J, Gambineri E, Hickey SE, Varga E, Markert ML. Mustillo PJ, et al. J Clin Immunol. 2023 Feb;43(2):247-270. doi: 10.1007/s10875-022-01418-y. Epub 2023 Jan 17. J Clin Immunol. 2023. PMID: 36648576 Free PMC article. Review. - Impact of Coronavirus Disease 2019 (COVID-19) on Patients With Congenital Heart Disease Across the Lifespan: The Experience of an Academic Congenital Heart Disease Center in New York City.
Lewis MJ, Anderson BR, Fremed M, Argenio M, Krishnan U, Weller R, Levasseur S, Sommer R, Lytrivi ID, Bacha EA, Vincent J, Chung WK, Rosenzweig EB, Starc TJ, Rosenbaum M; CUIMC Pediatric/Adult Congenital Heart Research Collaborative ‡. Lewis MJ, et al. J Am Heart Assoc. 2020 Dec;9(23):e017580. doi: 10.1161/JAHA.120.017580. Epub 2020 Oct 14. J Am Heart Assoc. 2020. PMID: 33196343 Free PMC article. - Follicular Helper T Cells in DiGeorge Syndrome.
Klocperk A, Paračková Z, Bloomfield M, Rataj M, Pokorný J, Unger S, Warnatz K, Šedivá A. Klocperk A, et al. Front Immunol. 2018 Jul 23;9:1730. doi: 10.3389/fimmu.2018.01730. eCollection 2018. Front Immunol. 2018. PMID: 30083170 Free PMC article. - Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome.
Suksawat Y, Sathienkijkanchai A, Veskitkul J, Jirapongsananuruk O, Visitsunthorn N, Vichyanond P, Pacharn P. Suksawat Y, et al. J Clin Immunol. 2017 May;37(4):375-382. doi: 10.1007/s10875-017-0394-6. Epub 2017 Apr 20. J Clin Immunol. 2017. PMID: 28429103 - Immunodeficiencies Associated with Abnormal Newborn Screening for T Cell and B Cell Lymphopenia.
Jyonouchi S, Jongco AM, Puck J, Sullivan KE. Jyonouchi S, et al. J Clin Immunol. 2017 May;37(4):363-374. doi: 10.1007/s10875-017-0388-4. Epub 2017 Mar 28. J Clin Immunol. 2017. PMID: 28353166 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous